Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 10/20 | 0.42 |
| ▸ | RAB9A | P51151 | 10/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18851551 | 0.81 | HDAC1 (0.49) | HDAC1HDAC2PTGS1PTGS2MEN1 | |
| SCHEMBL13325904 | 0.79 | RAB9A (0.65) | HDAC1PTGS1PTGS2MEN1KMT2A | |
| SCHEMBL871327 | 0.77 | PTGS1 (0.51) | HDAC1HDAC2PTGS1PTGS2MEN1 | |
| SCHEMBL27899681 | 0.77 | PTGS1 (0.47) | HDAC1HDAC2PTGS1PTGS2MEN1 | |
| SCHEMBL15033460 | 0.76 | PDE10A (0.55) | HDAC1HDAC2PTGS1PTGS2KDM4E | |
| SCHEMBL25395239 | 0.75 | HDAC1 (0.48) | HDAC1HDAC2PTGS1PTGS2MEN1 | |
| SCHEMBL25395244 | 0.75 | HDAC1 (0.48) | HDAC1HDAC2PTGS1PTGS2MEN1 | |
| SCHEMBL13325911 | 0.74 | RAB9A (0.63) | HDAC1PTGS1PTGS2MEN1KMT2A | |
| SCHEMBL19456997 | 0.72 | PTGS1 (0.47) | HDAC1HDAC2PTGS1PTGS2MEN1 | |
| SCHEMBL11819851 | 0.71 | KDM4E (0.48) | MEN1KMT2AKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136718-A1 | FUNCTIONALIZED LIPOSOMES FOR IMAGING MISFOLDED PROTEINS | Alzeca Biosciences, LLC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20200261605-A1 | FUNCTIONALIZED LIPOSOMES FOR IMAGING MISFOLDED PROTEINS | Alzeca Biosciences, LLC | 2020-08-20 | — | — | US | disclosed |
| WO-2020154623-A1 | FUNCTIONALIZED LIPOSOMES FOR IMAGING MISFOLDED PROTEINS | Alzeca Biosciences, LLC (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | US ARMY, SECRETARY OF THE ARMY | 2012-05-31 | — | — | US | disclosed |
| US-7998974-B2 | Fused heterocyclic compounds and their use as sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20090143376-A1 | Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators | SITRIS PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143376-A1 | Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators | SIRT1, SIRT3, SIRT2 | HDAC1 11/4885HDAC2 16/4885PTGS1 828/4885 |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | EP300, KAT2A, KAT6B | HDAC1 13/4885HDAC2 43/4885PTGS1 3012/4885 |
| US-20230136718-A1 | FUNCTIONALIZED LIPOSOMES FOR IMAGING MISFOLDED PROTEINS | APBA1, LYPLAL1, APOL1 | HDAC1 2932/4885HDAC2 4433/4885PTGS1 4022/4885 |
| US-20200261605-A1 | FUNCTIONALIZED LIPOSOMES FOR IMAGING MISFOLDED PROTEINS | APBA1, LYPLAL1, APOL1 | HDAC1 2932/4885HDAC2 4433/4885PTGS1 4022/4885 |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | HSF1, SIRT1, SIRT2 | HDAC1 32/4885HDAC2 44/4885PTGS1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.